

**REPLY UNDER 37 C.F.R. 1.116 –EXPEDITED PROCEDURE
TECHNOLOGY CENTER 1654**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1654	Customer No.: 035811
Examiner : Hemant Khanna	
Serial No. : 10/528,320	
Filed : March 17, 2005	
Inventors : Pascal Dumy	Docket No.: 1383-PCT-US-02
: Marie-Christine Favrot	
: Didier Boturyn	Confirmation No.: 4534
: Jean-Luc Coll	
Title : SYNTHESIS AND CHARACTERIZATION	
: OF NOVEL SYSTEMS FOR GUIDANCE	
: AND VECTORIZATION OF MOLECULES	
: OF THERAPEUTIC INTEREST TOWARDS	
: TARGET CELLS	

Dated: October 11, 2007

**REPLY UNDER 37 C.F.R. 1.116 –EXPEDITED PROCEDURE
TECHNOLOGY CENTER 1654**

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Response is submitted in response to the Official Action mailed on June 27, 2007.

Remarks

The Examiner has withdrawn Claims 67-68 and 69-92 from consideration until the claim drawn to the elected species is found allowable. Claims 60-62 and 66 have been examined on the merits.

Claims 60-62 and 66 remain rejected under 35 U.S.C. §103(a) over Scheibler in view of Kantlehner, and Rajopadhye. The rejection states that it would have been obvious to one skilled in the art in view of these documents to make a grafted homodetic cyclopeptide comprising the peptide derived from cyclo-(RGDfK) on one face and a detection agent on the other face. The rejection relies on Scheibler for teaching the homodetic cyclopeptide, and Kantlehner and Rajopadhye for teaching functionalization with a cyclo-(RGDfX) targeting agent and a diagnostic molecule.